Twist Bioscience Corp TWST
We take great care to ensure that the data presented and summarized in this overview for Twist Bioscience Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TWST
View all-
Artisan Partners Limited Partnership Milwaukee, WI6.02MShares$262 Million0.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.62MShares$245 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.42MShares$236 Million0.01% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl5.36MShares$234 Million2.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.64MShares$159 Million0.03% of portfolio
-
William Blair Investment Management, LLC Chicago, IL3.48MShares$152 Million0.4% of portfolio
-
State Street Corp Boston, MA3.17MShares$138 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.86MShares$125 Million0.09% of portfolio
-
Nikko Asset Management Americas, Inc.2.86MShares$125 Million1.5% of portfolio
-
Jpmorgan Chase & CO New York, NY2.48MShares$108 Million0.01% of portfolio
Latest Institutional Activity in TWST
Top Purchases
Top Sells
About TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Transactions at TWST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2025
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
5,000
-23.1%
|
$250,000
$50.0 P/Share
|
|
Jan 03
2025
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
546
-0.08%
|
$24,570
$45.59 P/Share
|
|
Jan 03
2025
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
160
-0.12%
|
$7,200
$45.59 P/Share
|
|
Jan 03
2025
|
Patrick John Finn President and COO |
SELL
Open market or private sale
|
Direct |
229
-0.08%
|
$10,305
$45.59 P/Share
|
|
Jan 03
2025
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
144
-0.13%
|
$6,480
$45.59 P/Share
|
|
Dec 20
2024
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,654
-0.25%
|
$72,776
$44.9 P/Share
|
|
Dec 20
2024
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
282
-0.21%
|
$12,408
$44.9 P/Share
|
|
Dec 20
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
316
-0.28%
|
$13,904
$44.9 P/Share
|
|
Dec 16
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
133
-0.12%
|
$6,118
$46.81 P/Share
|
|
Dec 06
2024
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
226
-0.42%
|
$11,752
$52.7 P/Share
|
|
Dec 06
2024
|
Emily M. Leproust Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,216
-0.33%
|
$115,232
$52.7 P/Share
|
|
Dec 06
2024
|
Paula Green SVP of Human Resources |
SELL
Open market or private sale
|
Direct |
860
-0.64%
|
$44,720
$52.7 P/Share
|
|
Dec 06
2024
|
Dennis Cho |
SELL
Open market or private sale
|
Direct |
367
-0.32%
|
$19,084
$52.7 P/Share
|
|
Dec 05
2024
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
3,504
-7.14%
|
$182,208
$52.08 P/Share
|
|
Dec 05
2024
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
3,504
+12.23%
|
$28,032
$8.82 P/Share
|
|
Dec 04
2024
|
Robert F. Werner Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,438
+13.67%
|
-
|
|
Dec 04
2024
|
Dennis Cho |
BUY
Grant, award, or other acquisition
|
Direct |
22,824
+16.68%
|
-
|
|
Dec 04
2024
|
Paula Green SVP of Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
20,428
+13.18%
|
-
|
|
Dec 04
2024
|
Adam Laponis Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,745
+18.74%
|
-
|
|
Dec 04
2024
|
Patrick John Finn President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
53,634
+16.34%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 554K shares |
|---|---|
| Exercise of conversion of derivative security | 7.1K shares |
| Payment of exercise price or tax liability | 12.6K shares |
|---|---|
| Open market or private sale | 169K shares |
| Grant, award, or other acquisition | 7.85K shares |